Gentile S, Persico M, Tiribelli C
Istituto Medicina Generale e Metodologia Clinica, I Facoltá di Medicina, Universitá di Napoli, Italy.
Hepatology. 1990 Aug;12(2):213-7. doi: 10.1002/hep.1840120206.
The plasma disappearance rate of sulfobromophthalein (VBSP; mumol/kg/min) was measured in 15 Gilbert's syndrome patients and 12 control subjects after intravenous injection of two different doses (0.59 and 5.90 mumol/kg) of the dye. Plasma disappearance rate was significantly reduced in Gilbert's syndrome patients after administration of 0.59 mumol sulfobromophthalein/kg (0.119 +/- 0.016 vs. 0.146 +/- 0.018 mumol/kg/min; mean +/- S.D.; p less than 0.001), whereas no difference was found with the higher dose (0.754 +/- 0.040 vs. 0.767 +/- 0.072 mumol/kg/min). Significant reduction was also found after administration to four Gilbert's syndrome patients and four control subjects of 0.29 and 2.95 mumol sulfobromophthalein (0.060 +/- 0.005 mumol/kg/min vs. 0.077 +/- 0.07 mumol/kg/min and 0.480 +/- 0.012 mumol/kg/min vs. 0.591 +/- 0.015 mumol/kg/min, respectively; p less than 0.01). Competition studies with combined administration of sulfobromophthalein (0.59 mumol/kg) and different doses of rifamycin SV (0.59, 1.47 and 2.95 mumol/kg) showed a significant (p less than 0.001) reduction in plasma disappearance rate in Gilbert's syndrome patients but not in controls. The rifamycin SV dose at which a 50% inhibition in plasma disappearance rate was observed was 0.8 mumol/kg. The apparent affinity (Km) of the hepatic transport was higher in Gilbert's syndrome patients than in control subjects (3.61 +/- 0.37 mumol sulfobromophthalein/kg vs. 2.76 +/- 0.29 mumol sulfobromophthalein/kg, mean +/- S.D.; p less than 0.01), whereas no difference was found in Vmax (0.95 +/- 0.11 mumol sulfobromophthalein/kg vs. 0.93 +/- 0.10 mumol sulfobromophthalein/kg/min, mean +/- S.D.; N.S.).(ABSTRACT TRUNCATED AT 250 WORDS)
在静脉注射两种不同剂量(0.59和5.90微摩尔/千克)的磺溴酞钠后,对15例吉尔伯特综合征患者和12名对照受试者测定了磺溴酞钠的血浆消失率(VBSP;微摩尔/千克/分钟)。给予0.59微摩尔磺溴酞钠/千克后,吉尔伯特综合征患者的血浆消失率显著降低(0.119±0.016对0.146±0.018微摩尔/千克/分钟;平均值±标准差;p<0.001),而给予较高剂量时未发现差异(0.754±0.040对0.767±0.072微摩尔/千克/分钟)。对4例吉尔伯特综合征患者和4名对照受试者给予0.29和2.95微摩尔磺溴酞钠后也发现显著降低(分别为0.060±0.005微摩尔/千克/分钟对0.077±0.07微摩尔/千克/分钟和0.480±0.012微摩尔/千克/分钟对0.591±0.015微摩尔/千克/分钟;p<0.01)。磺溴酞钠(0.59微摩尔/千克)与不同剂量利福霉素SV(0.59、1.47和2.95微摩尔/千克)联合给药的竞争研究表明,吉尔伯特综合征患者的血浆消失率显著降低(p<0.001),而对照受试者未降低。观察到血浆消失率50%抑制时的利福霉素SV剂量为0.8微摩尔/千克。吉尔伯特综合征患者肝脏转运的表观亲和力(Km)高于对照受试者(3.61±0.37微摩尔磺溴酞钠/千克对2.76±0.29微摩尔磺溴酞钠/千克,平均值±标准差;p<0.01),而Vmax未发现差异(0.95±0.11微摩尔磺溴酞钠/千克对0.93±0.10微摩尔磺溴酞钠/千克/分钟,平均值±标准差;无显著性差异)。(摘要截断于250字)